Neurol. praxi. 2019;20(5):356-360 | DOI: 10.36290/neu.2019.141

CGRP monoclonal antibodies for migraine prophylaxis

MUDr. Tomáš Nežádal, Ph.D.
Neurologické oddělení Ústřední vojenské nemocnice, Institut neuropsychiatrické péče,
1. lékařská fakulta Univerzity Karlovy, Praha

Prophylactic treatment of frequent episodic and chronic migraine is often unsuccessful. In recent years, the therapeutic procedures
have focused on the particular segments of the pathophysiological chain of migraine. Calcitonin Gene-Related Peptide (CGRP) is
a key peripheral and central agent. Data emerging from trials with monoclonal antibodies (mAb) suggest that this specific blockade
of the CGRP pathway may provide an effective and safe novel preventive therapeutical approach in migraine.

Keywords: migraine, CGRP antibodies, erenumab, fremanezumab, galcanezumab, eptinezumab

Published: November 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nežádal T. CGRP monoclonal antibodies for migraine prophylaxis. Neurol. praxi. 2019;20(5):356-360. doi: 10.36290/neu.2019.141.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. American Headache Society. The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practise. Headache 2019; 59(1): 1-18. Go to original source...
    2. Araki N, Takeshima T, Igarashi H, Shimizu T. Chronic Headache Clinical Practice Guideline Development Committee. Clinical Practice Guideline for Chronic Headache 2013. The Japanese Headache Society website.
    3. Baker B, Schaeffler B, Cady R, Latham J, Whitaker T, Smith J. Rational design of a monoclonal antibody inhibiting calcitonin gene-related peptide, ALD403 (eptinezumab), to provide early onset, high efficacy, extended duration of action, and desired safety for the prevention of migraine. Cephalalgia 2017; 37(1_suppl): 109. Go to original source...
    4. Camporeale A, Kudrow D, Sides R, Wang S, Van Dycke A, Selzler KJ, Stauffer VL. A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine. BMC Neurol. 2018; 18(1): 188. Go to original source... Go to PubMed...
    5. Depre C, Antalik L, Starling A, Koren M, Eisele O, Lenz RA, Mikol DD. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina. Headache 2018; 58(5): 715-723. Go to original source... Go to PubMed...
    6. Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine. Neurology 2018; 91(24): e2211-e2221. Go to original source... Go to PubMed...
    7. Diamond S, Bigal M, Silberstein SD, eLoder E, Reed M, Lipton RB. A Patterns of Diagnosis and Acute and Preventive Treatment for Migraine in the United States: Results from the American Migraine Prevalence and Prevention Study. Headache 2007; 47: 355-363. Go to original source...
    8. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF. PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010; 50(6): 921-936. Go to original source... Go to PubMed...
    9. Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. JAMA 2018; 319: 1999-2008. Go to original source... Go to PubMed...
    10. Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, Biondi D, Hirman J, Smith J. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. Cephalalgia 2019; 39(9): 1075-1085. Go to original source... Go to PubMed...
    11. Duncan C, Carod Artal FJ, Coulson A, O'Toole B, Scott S, Selvarajah J, Sharma S, Sleight C, Stein A, Watson DPB, West K. Scottish Intercollegiate Guidelines Network. Publication 155. Pharmacological management of migraine. A national clinical guideline. Edinburg: SIGN; February 2018.
    12. Edvinsson L. The CGRP Pathway in Migraine as a Viable Target for Therapies. Headache. 2018 May; 58 Suppl 1: 33-47. Go to original source... Go to PubMed...
    13. Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sándor PS. European Federation of Neurological Societies; EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur J Neurol. 2009 Sep; 16(9): 968-981. Go to original source... Go to PubMed...
    14. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28: 183-187. Go to original source... Go to PubMed...
    15. Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med 2017; 377: 2123-2132. Go to original source... Go to PubMed...
    16. Goadsby PJ, Dodick DW, Leone M, Bardos JN, Oakes TM, Millen BA, Zhou C, Dowsett SA, Aurora SK, Ahn AH, Yang JY, Conley RR, Martinez JM. Trial of Galcanezumab in Prevention of Episodic Cluster Headache. N Engl J Med 2019; 381(2): 132-141. Go to original source... Go to PubMed...
    17. Hepp, Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 2015; 35(6): 478-488. Go to original source... Go to PubMed...
    18. Juhasz G, Zsombok T, Jakab B, Nemeth J, Szolcsanyi J, Bagdy G. Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack. Cephalalgia 2005; 25: 179-183. Go to original source... Go to PubMed...
    19. Kamm K, Straube A, Ruscheweyh R. Calcitonin gene-related peptide levels in tear fluid are elevated in migraine patients compared to healthy controls. Cephalalgia 2019; https://doi.org/10.1177/0333102419856640. Go to original source... Go to PubMed...
    20. Lipton RB, Saper J, Ashina M, Lipton RB, Saper J, Ashina M, Biondi D, Bhattacharya S, Hirman J, Schaeffler B, Cady R. A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of eptinezumab for the preventive treatment of chronic migraine: Results of the PROMISE-2 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-2) trial. Neurology 2018; 90: E2193-E2194u.
    21. Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, Klatt J. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 2018; 392(10161): 2280-2287. Go to original source... Go to PubMed...
    22. Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, Martelletti P. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 2019; 20(1): 6. Go to original source... Go to PubMed...
    23. Saper J, Lipton RB, Kudrow DB, Hirman J, Dodick D, Silberstein S, Chakhava G, Smith J, Biondi D. A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of eptinezumab in frequent episodic migraine prevention: Primary results of the PROMISE-1 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-1) trial. Cephalalgia 2017; 37(1_suppl): 337.
    24. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78(17): 1337-45. Go to original source... Go to PubMed...
    25. Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med. 2017; 377(22): 2113-2122. Go to original source... Go to PubMed...
    26. Silberstein SD, McAllister P, Ning X, Faulhaber N, Lang N, Yeung P, Schiemann J, Aycardi E, Cohen JM, Janka L, Yang R. Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials. Headache 2019; 59(6): 880-890. Go to original source... Go to PubMed...
    27. Skljarevski V, Matharu, M, Millen, BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia 2018; 38(8): 1442-1454. Go to original source... Go to PubMed...
    28. Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial. JAMA Neurol 2018; 75(9): 1080-1088. Go to original source... Go to PubMed...
    29. Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, Winner P, Leonardi D, Mikol D, Lenz R. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 2017; 16: 425-434. Go to original source... Go to PubMed...
    30. VanderPluym J, Dodick DW, Lipton RB, Ma Y, Loupe PS, Bigal ME. Fremanezumab for preventive treatment of migraine: Functional status on headache-free days. Neurology 2018; 91(12): e1152-e1165. Go to original source... Go to PubMed...
    31. World Health Organization. World Health Statistics 2013 (A Wealth Of Information Of Global Public Health). WHO Document Production Services: Switzerland, Geneva: 1-168.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.